Ian D. Schnadig

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · The Lancet Oncology · 2022 · 162 citations · Full text

Urology, Oncology, Metastatic Urothelial Carcinoma +7

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial

Lee S. Schwartzberg, Manuel Modiano, Bernardo L. Rapoport et al. · The Lancet Oncology · 2015 · 149 citations

Emetogenic Chemotherapy, Oncology, Cyclophosphamide Regimens +9

Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials

Bernardo L. Rapoport, Martin Chasen, Cesare Gridelli et al. · The Lancet Oncology · 2015 · 139 citations

Emetogenic Chemotherapy, Chemotherapy-induced Nausea, Gastrointestinal Oncology +7